Format

Send to

Choose Destination
Cancer Lett. 2013 Oct 10;339(2):237-46. doi: 10.1016/j.canlet.2013.06.014. Epub 2013 Jun 18.

Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo.

Author information

1
Vincent Center for Reproductive Biology, Department of Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA.

Abstract

Development of recurrent platinum resistant disease following chemotherapy presents a challenge in managing ovarian cancer. Using tumors derived from genetically defined mouse ovarian cancer cells, we investigated the stem cell properties of residual cells post-chemotherapy. Utilizing CD133 and Sca-1 as markers of candidate tumor initiating cells (TIC), we determined that the relative levels of CD133+ and Sca-1+ cells were unaltered following chemotherapy. CD133+ and Sca-1+ cells exhibited increased stem cell-related gene expression, were enriched in G0/G1-early S phase and exhibited increased tumor initiating capacity, giving rise to heterogeneous tumors. Our findings suggest that residual TICs may contribute to recurrent disease.

KEYWORDS:

CD133 cells; Ovarian cancer tumor initiating cells; Sca-1 cells

PMID:
23791886
DOI:
10.1016/j.canlet.2013.06.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center